Straits Times Index
3,300.04 -3.15 (-0.10%) S&P 500
5,196.62 +15.88 (+0.31%) Dow
38,923.24 +70.97 (+0.18%) Nasdaq
16,384.05 +34.81 (+0.21%) Bitcoin USD
63,364.65 -40.84 (-0.06%) CMC Crypto 200
1,317.71 -47.41 (-3.47%)
Vertex Pharmaceuticals Incorporated (VRTX)
| Previous close | 402.50 |
| Open | 406.42 |
| Bid | 410.27 x 100 |
| Ask | 410.99 x 100 |
| Day's range | 394.03 - 415.67 |
| 52-week range | 320.01 - 448.40 |
| Volume | |
| Avg. volume | 1,036,791 |
| Market cap | 106.181B |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | 29.58 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Vertex Reports First Quarter 2024 Financial Results
BOSTON, May 06, 2024--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the first quarter ended March 31, 2024, and reiterated full year 2024 financial guidance.
- Business Wire
Vertex Announces European Commission Approval for KALYDECO® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older
LONDON, April 26, 2024--Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R.
- CNW Group
VERTEX AND TREEFROG THERAPEUTICS ANNOUNCE LICENSING AGREEMENT AND COLLABORATION TO OPTIMIZE PRODUCTION OF VERTEX'S CELL THERAPIES FOR TYPE 1 DIABETES
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and TreeFrog Therapeutics today announced that Vertex has obtained an exclusive license to TreeFrog's proprietary cell manufacturing technology, C-StemTM, to optimize production of Vertex's cell therapies for type 1 diabetes (T1D). TreeFrog and Vertex will collaborate to scale-up TreeFrog's process to produce and amplify cells for Vertex's T1D therapies.
